Cytori Therapeutics, Inc. Appoints Gregg Lapointe as an Independent Director
April 03, 2017 at 05:30 pm IST
Share
Cytori Therapeutics, Inc. announced that Gregg Lapointe has joined the Company’s Board of Directors to serve as an independent director, effective March 31, 2017. Mr. Lapointe has over 20 years of experience in the pharmaceutical and medical device industries. He is a Co-Founder and currently serves as the CEO of Cerium Pharmaceuticals. Previously, he held several managerial and executive roles at Sigma-Tau Pharmaceuticals including serving as CEO from 2008 to 2012. Mr. Lapointe currently serves as a member of the Board of Directors of SciClone Pharmaceuticals, Soligenix and Immunocellular Therapeutics and on the Board of Trustees of the Keck Graduate Institute of Applied Life Sciences.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Companyâs Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.
PLUS THERAPEUTICS, INC. 
